Symbiotec Pharmalab IPO: Date, Price, GMP & Review | Finowings

Symbiotec Pharmalab IPO- Complete Overview 

Symbiotec Pharmalab IPO is a Mainboard IPO with an issue size of Rs. 1,757 Cr by Symbiotec Pharmalab Limited, which is a pharmaceutical and biotechnology firm that develops and produces specialty goods, nutritional supplements, and active pharmaceutical compounds. The business serves both home and foreign markets in both developed and developing nations.

It places a strong emphasis on sustainable methods, quality compliance, and manufacturing that is driven by research. Symbiotec Pharmalab Ltd. provides premium, cutting-edge chemicals that meet international standards to help the pharmaceutical, nutraceutical, and wellness sectors.

With more than 30 years of experience in the industry, they have developed from a lab-scale manufacturer of steroidal-hormone APIs in 1995 to an industrial-scale, backward-integrated platform with approvals from the US Food and Drug Administration ("US FDA"), European Union Good Manufacturing Practices ("EU-GMP"), Korea's Ministry of Food and Drug Safety, and other international organizations.

This new IPO is to be launched on 24 Aug 2026, and its ‘initial public offering’ will end on 27 Aug 2026.

Symbiotec Pharmalab IPO Details

This Mainline IPO comprises a combination of a fresh issue of 0.15 crore shares (Rs. 150 Cr) and an offer for sale of 1.63 crore shares (Rs. 1607 Cr). The Symbiotec Pharmalab IPO listing date (expected) might be Tuesday, Sep 01, 2026, and the listing on the BSE and SME. 

The Symbiotec Pharmalab IPO price band is Rs. 938 to Rs. 988.

IPO Timetable (Tentative)

The Symbiotec IPO date is from 24 Aug to 27 Aug, with IPO allotment on Aug 28, refund initiation on Aug 31, and listing on Sep 01, 2026.

Refund Initiation 

If you want to apply for the IPO, click to open a Demat Account.

Industry Overview & Outlook

The India CDMO market was valued at USD 3.8 billion in 2020 and grew at a robust CAGR of 13.3% to reach USD 7.1 billion in 2025. It is projected to expand at a CAGR of 13.5%, reaching USD 13.4 billion by 2030F.

Company Financial

(Amount in Cr)

Cash Flows

The cash flows for various activities are shown below:

(Amount in Mn)

Revenue Bifurcation 

(Source: RHP)

The Objective of the Issue

• Prepayment and/or repayment, in full or in part, of all or a portion of certain outstanding borrowings availed by the Company. ~ Rs. 112.50 Cr.

• General Corporate Purposes.

Peers of Symbiotec Pharmalab

Evaluation of P/E Ratio

Considering the period ended on FY 2026 with an EPS of Rs. 19.10 from the last year, the resulting P/E ratio is 25.49x.

The Lalithaa Jewellery Mart IPO application will be available from 17 August 2026.

Symbiotec Pharmalab IPO Valuation

Symbiotec Pharmalab share price

Symbiotec Pharmalab share price is not yet available as the company is in the IPO phase. 

IPO's Strengths

• Leading the world in steroidal-hormone and corticosteroid APIs

• Long-standing connections with a domestic and international clientele

• Fully funded, vertically integrated, multi-scale manufacturing platform with a spotless regulatory record and sustainable practices.

• Constant R&D investment, with superior technological prowess compared to Indian counterparts.

IPO's Weaknesses

• Customers and regulatory bodies periodically check and audit the company's manufacturing facilities. Any manufacturing or quality control failure could lead to negative repercussions on business and financial performance, reputational harm, and regulatory action.

• Customers outside of India account for a sizable amount of the company's revenue, accounting for 66.67%, 55.19%, 59.97%, and 52.76% of operating revenue in the three months ending June 30, 2025, and Fiscal 2025, 2024, and 2023, respectively.

• A percentage of the company's raw material needs are sourced from nations like China and the US. Any unfavorable events in these nations or modifications to the import regulations could interfere with the raw material supply and negatively impact the business's operational outcomes.
  
  

Symbiotec Pharmalab IPO GMP Today

Symbiotec Pharmalab IPO GMP has not started yet as of August 19, 2026, when this information was written. 

IPO Other Details

IPO Grey Market Premium

The current IPO GMP is available at our live IPO GMP page, where you can get the GMP today for open Mainboard and SME IPOs.

Symbiotec Pharmalab IPO Lot Size

The IPO allows retail investors to invest in a minimum and maximum of 1 Lot (15 Shares) amounting to Rs. 14,820 and 13 Lots (195 Shares) for Rs. 1,92,660, respectively, while for HNI investors, the minimum Lot is 14 (210 Shares) amounting to Rs. 2,07,480.

IPO Reservation

Promoters and Management of Symbiotec Pharmalab Ltd. 

• Anil Satwani

• Kashish Satwani

• Sushil Satwani 

• Satwani Holdings LLP.
  
  

IPO Lead Managers

JM Financial Ltd. 

Dividend Policy

The company has not paid a dividend during the last three FYs.

Conclusion

Symbiotec Pharmalab IPO offers investors exposure to a well-established pharmaceutical API manufacturer with strong global operations, regulatory approvals, and consistent profitability. The IPO is priced at ₹938–₹988 per share, while its growth prospects are supported by rising CDMO demand, a diversified customer base, and continued R&D investment.

Other Open Mainboard IPOs 2026

Shiprocket IPO 

Shiprocket IPO GMP is Rs. 33, showing a gain of 34.02% as of 12 Aug 2026.

Dhoot Transmission IPO

Dhoot Transmission IPO was open from 10-12 August 2026.

Molbio Diagnostics IPO

Molbio Diagnostics IPO was open from 10-12 August 2026.

Ardee Industries Share Price

Ardee Industries Share Price was Rs. 67.1 as of 12 August 2026.

Milky Mist IPO

Milky Mist Dairy IPO is open from 11-13 August 2026.

Click Here to Stay Updated With The Upcoming IPOs.

Finowings IPO Analysis

Hope you enjoyed the Finowings IPO Analysis. We tried our best to give every required detail about the company that you should know before applying to the IPO.

You must consult your financial advisor before making any financial decisions.

To Apply for the IPO, Click Here.

To Read the Prospectus of the Company Click Here to Download the DRHP.

Click Here To Stay Updated With The Upcoming IPOs.

DISCLAIMER: This blog is NOT any buy or sell recommendation. No investment or trading advice is given. The content is purely for educational and information purposes only. Always consult your eligible financial advisor for investment-related decisions.